Anti-CD8α Antibody (OKT-8) 

Anti-CD8α Antibody (OKT-8) is an anti-human CD8α IgG2a monoclonal antibody. Anti-CD8α Antibody (OKT-8) can reduce the secretion of IFNγ. Anti-CD8α Antibody (OKT-8) can deplete CD8⁺ T cells. Anti-CD8α Antibody (OKT-8) can be used for researches on inflammation conditions and cancer such as B non-Hodgkin lymphomas (B-NHLs). The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978)^[1][2].

Mouse IgG2a kappa

Mouse IgG2a kappa, Isotype Control

Human

CD8α

Anti-CD8α Antibody (OKT-8) (10 μg/mL, 18-24 h) can significantly block IFNγ secretion in CD4⁺ TEG011_CD8α cells^[1].
Anti-CD8α Antibody (OKT-8) (18-24 h) significantly inhibits tumor reactivity of TEG011_CD8 α cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-CD8α Antibody (OKT-8) (100-200 μg, i.p., twice weekly, for 4 weeks) can deplete CD8⁺ T cells in NSG mice with a B non-Hodgkin lymphomas (B-NHLs) xenograft model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

925  [NCBI]

P01732

in vivo CD8+ T cell depletion in humanized mice

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

147.89 kDa

Liquid

Colorless to light yellow

[Anti-CD8a Antibody (OKT-8)]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Flow cytometric analysis of 1X10⁶ Jurkat cells with Anti-CD8α Antibody (OKT-8) (HY-P990855, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Mouse IgG H&L (HY-P8005) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Mouse IgG2a kappa (HY-P99978, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
• 
  Immobilized CD8 alpha Protein, Human (HEK293, His, HY-P71662) can bind Anti-CD8α Antibody (OKT-8). The EC₅₀ for this effect is 13.50 ng/mL.

• [1]. Johanna I, et al. Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor Control. Front Immunol. 2021 Oct 25;12:752699.  [Content Brief]

  [2]. Daneels W, et al. High efficacy of huCD20-targeted AcTaferon in humanized patient derived xenograft models of aggressive B cell lymphoma. Exp Hematol Oncol. 2024 Jun 3;13(1):59.  [Content Brief]